Merck

Chasing Roche, Merck talks up subcutaneous Keytruda ahead of phase 3 data drop
Chasing Roche, Merck talks up subcutaneous Keytruda ahead of phase 3 data drop
Fierce Pharma
Merck
Keytruda
Roche
cancer
oncology
Flag link:
Big caps bounce back for biopharma
Big caps bounce back for biopharma
EP Vantage
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Flag link:
Three TIGIT players look to surprise in 2023
Three TIGIT players look to surprise in 2023
EP Vantage
anti-TIGIT
Roche
Merck
Gilead Sciences
Arcus Biosciences
Flag link:
Biopharma’s bolt-on bonanza is set to continue
Biopharma’s bolt-on bonanza is set to continue
EP Vantage
M&A
Amgen
AstraZeneca
Bristol Myers Squibb
GSK
Ipsen
Merck
Pfizer
Flag link:
Merck Highlights Growth Strategy at J.P. Morgan
Merck Highlights Growth Strategy at J.P. Morgan
BioSpace
Merck
JPMHC 2023
Keytruda
vaccines
M&A
Flag link:
JPM23, Day 2: Takeda readies for dengue vaccine launch; Merck touts recent deals
JPM23, Day 2: Takeda readies for dengue vaccine launch; Merck touts recent deals
Fierce Pharma
JPMHC 2023
Takeda
vaccines
Roche
GSK
Bayer
Merck
Flag link:
Novo Nordisk, AstraZeneca and Lilly will top pharma's revenue growth in 2023: report
Novo Nordisk, AstraZeneca and Lilly will top pharma's revenue growth in 2023: report
Fierce Pharma
Pfizer
Merck
JNJ
Novo Nordisk
AstraZeneca
Flag link:
The biggest-selling pharma companies of 2023
The biggest-selling pharma companies of 2023
EP Vantage
Pfizer
Merck
JNJ
Novartis
AbbVie
Roche
Flag link:
Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts
Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts
Fierce Pharma
Eli Lilly
Merck
PeptiDreams
peptides
drug delivery
Flag link:
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
Biopharma Reporter
antibody-drug conjugate
Merck
LegoChem Biosciences
Mersana
Amgen
GSK
Janssen
Flag link:
OncoC4 doses first participant in ovarian cancer therapy trial
OncoC4 doses first participant in ovarian cancer therapy trial
Clinical Trials Arena
OncoC4
clinical trials
ONC-392
Merck
Keytruda
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
BioSpace
Merck
China
Kelun-Biotech
antibody-drug conjugate
oncology
Flag link:
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay
Fierce Pharma
AstraZeneca
Merck
Lynparza
Europe
prostate cancer
advanced prostate cancer
Flag link:
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Fierce Biotech
Merck
NGM Biopharmaceuticals
clinical trials
eye disease
NGM621
geographic atrophy
Flag link:
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
metastatic castration-resistant prostate cancer
Flag link:
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
Fierce Biotech
Merck
Moderna Therapeutics
MRNA
cancer immunotherapy
Keytruda
melanoma
Flag link:
Merck initiates cash tender offer to buy Imago BioSciences
Merck initiates cash tender offer to buy Imago BioSciences
Pharmaceutical Business Review
Merck
M&A
Imago BioSciences
Flag link:
Setting the Stage for ASH 2022
Setting the Stage for ASH 2022
BioSpace
ASH 2022
AstraZeneca
Janssen
Merck
Vega Therapeutics
Flag link:
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Yahoo/Reuters
Mirati Therapeutics
adagrasib
Merck
Keytruda
metastatic lung cancer
lung cancer
Flag link:
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance
Fierce Pharma
GSK
Merck
Jemperli
Keytruda
clinical trials
non-small cell lung cancer
Flag link:

Pages